Table 6.
Toxicity data during follow-up
| Fibrosis | Grade 0 | 113/138 | (81.9%) |
| Grade 1 | 21/138 | (15.2%) | |
| Grade 2 | 4/138 | (2.9%) | |
| Grade 3 | 0/116 | (0%) | |
| Grade 4 | 0/116 | (0%) | |
| Hyperpigmentation | Grade 0 | 98/138 | (71.0%) |
| Grade 1 | 34/138 | (24.6%) | |
| Grade 2 | 6/138 | (4.4%) | |
| Grade 3 | 0/138 | (0%) | |
| Grade 4 | 0/138 | (0%) | |
| Lymphedema breast | Grade 0 | 120/138 | (87.0%) |
| Grade 1 | 12/138 | (8.7%) | |
| Grade 2 | 6/138 | (4.3%) | |
| Grade 3 | 0/138 | (0%) | |
| Grade 4 | 0/138 | (0%) | |
| Lymphedema arm | Grade 0 | 128/138 | (92.7%) |
| Grade 1 | 7/138 | (5.1%) | |
| Grade 2 | 3/138 | (2.2%) | |
| Grade 3 | 0/138 | (0%) | |
| Grade 4 | 0/138 | (0%) | |
| Lung fibrosis | Grade 0 | 135/138 | (97.8%) |
| Grade 1 | 3/138 | (2.2%) | |
| Grade 2 | 0/138 | (0%) | |
| Grade 3 | 0/138 | (0%) | |
| Grade 4 | 0/138 | (0%) |